Dechra gains from bullish note from house broker Investec
11th Jun 2014 15:39
Broker Investec put out a bullish note on corporate broking client Dechra Pharmaceuticals, urging investors to "take a fresh look" at the veterinary pharmaceuticals specialist. Analysts Nicholas Keher and Cora McCallum argued that "revenue headwinds are normalising, its pipeline is starting to del
Read moreFTSE 250 movers: Broker comment pushes Dechra Pharma higher
11th Jun 2014 14:34
Investec helped Dechra Pharmaceuticals into the top 10 after reiterating its 'buy' rating and upping its target price from 787p to 842p. Online betting exchange Betfair thrashed analysts' full-year forecasts as management tackled the cost base and the introduction of a more traditional bookmaker's
Read moreWednesday broker round-up UPDATE
11th Jun 2014 09:05
ASOS: Berenberg reduces target price from 5350p to 3785p, while its buy recommendation is kept. Babcock International: Citi reduces target price from 1320p to 1280p and retains a neutral rating. Cobham: UBS raises target price from 290p to 315p and keeps a neutral rating. Dechra Pharmaceuticals:
Read moreDechra Pharmaceuticals acquires assets of PSPC
20th May 2014 10:29
Dechra Pharmaceuticals has snapped up the assets of veterinary products maker PSPC Inc. for 10m dollars, strengthening its US product portfolio. The firm's main product is Phycox, which currently generates sales of around $4.5m a year in North America. A new product is in the final phase of deve
Read moreDechra Pharmaceuticals receives marketing approvals
2nd May 2014 13:25
Pharmaceuticals group Dechra announced it has received marketing approval from the US Food and Drug Administration and the UK Veterinary Medicines Directorate for its Equine Lameness Product and US Ophthalmics. The group's new product, Osphos, is expected to be launched towards the start of the nex
Read moreDechra speeds growth in third quarter thanks to US bounce
30th Apr 2014 09:28
- Q3 sales up 4.7 per cent - US sales up 16.3 per cent - Europe up 3.3 per cent - European CAP up but FAP flat and antibiotics down Strong sales growth in the US helped veterinary products maker Dechra Pharmaceuticals accelerate revenues in a strong third quarter, in line with management expectati
Read moreFTSE 250 movers: Ashmore dives as profits sink by a third
25th Feb 2014 15:30
Asset manager Ashmore was at the bottom of the pile after its first-half profits fell by a third as it counted the cost of investor wariness over emerging markets against a backdrop of the US winding down its bond-buying stimulus programme. The news prompted Canaccord to downgrade the stock to 'hold
Read moreDechra Pharma H1 profits up but Netherlands disappoints
25th Feb 2014 08:50
Veterinary drug group Dechra Pharmaceuticals boosted half-year revenue in most of its markets but a disappointing performance in the Netherlands, the phasing of export orders and US supply issues hit trading. Dechra, which makes or markets products such as cat sedative Alfaxan and dog endocrinology
Read moreTuesday broker round-up UPDATE
25th Feb 2014 08:40
African Barrick Gold: Canaccord Genuity raises target price from 205p to 315p and upgrades from hold to buy. Ashmore Group: Canaccord Genuity takes target price from 205p to 315p and downgrades from buy to hold. Associated British Foods: Jefferies increases target price from 2450p to 2600p retaini
Read moreFTSE 250 movers: Ocado rises ahead of trading update
13th Jan 2014 15:29
Ocado was rising strongly ahead of its trading update on Thursday, when the group is expected to post a robust set of figures for the Christmas period. The internet grocer is expected to have benefitted from the trend that has seen retailers move their shopping habits online. The share price of de
Read moreTough European markets weigh on Dechra Pharm
13th Jan 2014 07:40
- Half-year revenue rises despite tough European markets - Netherlands hit by lower antimicrobial demand, increased competition - Strong growth of key products in US, supply issues at Animax Veterinary pharmaceuticals group Dechra Pharmaceuticals said revenue improved around four per cent from th
Read moreDechra warns on first quarter export and US revenues
17th Oct 2013 14:05
Dechra, the FTSE 250 specialist veterinary pharmaceuticals business, on Thursday revealed that first-quarter export revenues were lower than the previous year, which more than offset the 'robust' growth of four per cent seen within its own sales and marketing organisations. In its European Pharmace
Read moreThursday broker round-up UPDATE
17th Oct 2013 09:45
AGA Rangemaster Group: N+1 Singer ups target price from 135p to 150p and stays with its buy recommendation. Anglo American: HSBC raises target price from 1610p to 1740p maintaining an overweight rating. Antofagasta: HSBC increases target price from 900p to 990p and upgrades to overweight. Aquariu
Read moreLondon close: Fed uncertainty, US debt ceiling weigh on stocks
23rd Sep 2013 16:27
Concerns about the US economy weighed heavily on global stock markets on Monday as investors focused on comments from Federal Reserve officials and the ongoing debt-ceiling debate. The FTSE 100 finished down 39.06 points on the day at 6,557.37. "Those of the opinion that stock markets have oversho
Read moreFTSE 250 movers: Dechra Pharmaceuticals lifted by broker upgrade
23rd Sep 2013 14:48
Veterinary pharmaceuticals group Dechra Pharmaceuticals got a boost after it booked more than a 50 per cent increase in full year revenue, which was slightly ahead of expectations at Investec. The broker upgraded the stock from 'add' to 'buy' and raised its target price from 708p to 788p, saying "re
Read more